Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Memantine HCl Clear all
Active, not recruiting Phase 3 Interventional

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

NCT04804644
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
227
States / cities
Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

NCT05045950
View directory record Official record
Conditions
Brain Metastases
Interventions
Memantine -Twice Daily or Extended Release, WBRT utilizing the PRDR technique
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

NCT00136747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine, bupropion, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 29, 2026, 10:04 PM EDT
Terminated Phase 4 Interventional

Namenda to Prevent Post-Operative Delirium

NCT00303433
View directory record Official record
Conditions
Delirium, Post-Operative States
Interventions
Namenda
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine as a Supplement to Naltrexone in Treating Heroin Dependence

NCT00476242
View directory record Official record
Conditions
Opioid Dependence, Heroin Dependence
Interventions
Vivitrol, memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

NCT01592747
View directory record Official record
Conditions
Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl), Placebo capsules
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
64
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 29, 2026, 10:04 PM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 29, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

NCT07470606
View directory record Official record
Conditions
Brain Tumor
Interventions
Memantine, Raloxifene
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Terminated Phase 3 Interventional

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

NCT03553875
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Interventions
Memantine Hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

NCT06789757
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Memantine Hydrochloride, Bevacizumab, Atezolizumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment Resistant Geriatric Depression in Primary Care

NCT01392287
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 29, 2026, 10:04 PM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

NCT07248228
View directory record Official record
Conditions
Brain Metastases
Interventions
MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)), Memantine
Radiation · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

NCT00000867
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Memantine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

NCT00476008
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Memantine, Placebo
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

NCT01585168
View directory record Official record
Conditions
Healthy
Interventions
Memantine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 29, 2026, 10:04 PM EDT
Recruiting Phase 1 Interventional

Pattern Separation in Major Depressive Disorder

NCT07139834
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
Drug
Lead sponsor
Jeffrey Miller
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 29, 2026, 10:04 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

NCT02080364
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
80
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions
memantine hydrochloride, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 29, 2026, 10:04 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

NCT00988663
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
Jerrry L Lewis
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 29, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional Results available

Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

NCT02234752
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Galantamine ER, Memantine XR
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 29, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 29, 2026, 10:04 PM EDT